Bradykinin and des-Arg9-bradykinin metabolic pathways and kinetics of activation of human plasma

Mélanie Cyr, Yves Lepage, Charles Blais, Nicole Gervais, Massimo Cugno, Jean Lucien Rouleau, Albert Adam

Research output: Contribution to journalArticlepeer-review


In the serum of 116 healthy individuals, exogenous bradykinin (BK) half-life (27 ± 10 s) was lower than that of des-Arg9-BK (643 ± 436 s) and was statistically different in men compared with women. The potentiating effect of an angiotensinconverting enzyme (ACE) inhibitor was, however, more extensive for BK (9.0-fold) than for des-Arg9-BK (2.2-fold). The activities of ACE, aminopeptidase P (APP), and kininase I were respectively 44 ± 12, 22 ± 9, and 62 ± 10 nmol·min-1·ml-1. A mathematical model (y = ktαe-βt, t > 0), applied to the BK kinetically released from endogenous high-molecular-weight kininogen (HK) during plasma activation in the presence of an ACE inhibitor, revealed a significant difference in the rate of formation of BK between men and women. For des-Arg9-BK, the active metabolite of BK, the rate of degradation was higher in women compared with men, correlating significantly with serum APP activity (r2 = 0.6485, P <0.001). In conclusion, these results constitute a basis for future pathophysiological studies of inflammatory processes where activation of the contact system of plasma and the kinins is involved.

Original languageEnglish
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Issue number1 50-1
Publication statusPublished - 2001


  • Angiotensin-converting enzyme inhibitors
  • Contact system activation
  • Kinins

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)


Dive into the research topics of 'Bradykinin and des-Arg9-bradykinin metabolic pathways and kinetics of activation of human plasma'. Together they form a unique fingerprint.

Cite this